These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 16689755)

  • 1. Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease.
    Undas A; Celinska-Löwenhoff M; Löwenhoff T; Szczeklik A
    J Thromb Haemost; 2006 May; 4(5):1029-36. PubMed ID: 16689755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered fibrin clot properties in patients with retinal vein occlusion.
    Karska-Basta I; Kubicka-Trząska A; Romanowska-Dixon B; Undas A
    J Thromb Haemost; 2011 Dec; 9(12):2513-5. PubMed ID: 21955304
    [No Abstract]   [Full Text] [Related]  

  • 3. Atorvastatin and quinapril inhibit blood coagulation in patients with coronary artery disease following 28 days of therapy.
    Undas A; Brummel-Ziedins KE; Potaczek DP; Stobierska-Dzierzek B; Bryniarski L; Szczeklik A; Mann KG
    J Thromb Haemost; 2006 Nov; 4(11):2397-404. PubMed ID: 16907931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of atorvastatin on haemostasis, fibrinolysis and inflammation in normocholesterolaemic patients with coronary artery disease: a post hoc analysis of data from a prospective, randomized, double-blind study.
    Walter T; Szabo S; Suselbeck T; Borggrefe M; Lang S; Swoboda S; Hoffmeister HM; Dempfle CE
    Clin Drug Investig; 2010; 30(7):453-60. PubMed ID: 20441243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simvastatin increases clot permeability and susceptibility to lysis in patients with LDL cholesterol below 3.4 mmol/l.
    Undas A; Topór-Madry R; Tracz W
    Pol Arch Med Wewn; 2009 Jun; 119(6):354-9. PubMed ID: 19694216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease.
    Waehre T; Damås JK; Gullestad L; Holm AM; Pedersen TR; Arnesen KE; Torsvik H; Frøland SS; Semb AG; Aukrust P
    J Am Coll Cardiol; 2003 May; 41(9):1460-7. PubMed ID: 12742282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia.
    Milionis HJ; Papakostas J; Kakafika A; Chasiotis G; Seferiadis K; Elisaf MS
    J Clin Pharmacol; 2003 Aug; 43(8):825-30. PubMed ID: 12953339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma homocysteine affects fibrin clot permeability and resistance to lysis in human subjects.
    Undas A; Brozek J; Jankowski M; Siudak Z; Szczeklik A; Jakubowski H
    Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1397-404. PubMed ID: 16574890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The angiotensin-converting enzyme gene insertion/deletion polymorphism and effects of quinapril and atorvastatin on haemostatic parameters in patients with coronary artery disease.
    Potaczek DP; Undas A; Iwaniec T; Szczeklik A
    Thromb Haemost; 2005 Jul; 94(1):224-5. PubMed ID: 16116691
    [No Abstract]   [Full Text] [Related]  

  • 10. Synergistic effect of angiotensin-converting enzyme (ACE) and 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibition on inflammatory markers in atherosclerotic rabbits.
    Oubiña MP; de las Heras N; Cediel E; Sanz-Rosa D; Aragoncillo P; Díaz C; Hernández G; Lahera V; Cachofeiro V
    Clin Sci (Lond); 2003 Dec; 105(6):655-62. PubMed ID: 12848617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of atorvastatin, simvastatin, and fenofibrate therapy on monocyte chemoattractant protein-1 secretion in patients with hyperlipidemia.
    Kowalski J; Okopień B; Madej A; Zieliński M; Belowski D; Kalina Z; Herman ZS
    Eur J Clin Pharmacol; 2003 Jul; 59(3):189-93. PubMed ID: 12756509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy with high-dose statins reduces soluble P-selectin: The impact on plasma fibrin clot properties.
    Siudut J; Pudło J; Konieczyńska M; Polak M; Jawień J; Undas A
    Int J Cardiol; 2023 Feb; 373():110-117. PubMed ID: 36410546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia.
    Undas A; Celinska-Löwenhoff M; Domagala TB; Iwaniec T; Dropinski J; Löwenhoff T; Szczeklik A
    Thromb Haemost; 2005 Jul; 94(1):193-9. PubMed ID: 16113803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
    Sharma R; Mahajan M; Singh B; Bal BS; Kant R
    J Indian Med Assoc; 2006 Sep; 104(9):492-4, 496, 498. PubMed ID: 17388006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers.
    Penn R; Williams RX; Guha-Ray DK; Sawyers WG; Braun SL; Rains KT
    Clin Ther; 2006 Jan; 28(1):45-54. PubMed ID: 16490579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensive low-density lipoprotein cholesterol lowering improves fibrin clot properties: Association with lipoproteins and C-reactive protein.
    Siudut J; Ząbczyk M; Wołkow P; Polak M; Undas A; Jawień J
    Vascul Pharmacol; 2022 Jun; 144():106977. PubMed ID: 35283275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated factor XIa as a modulator of plasma fibrin clot properties in coronary artery disease.
    Paszek E; Malinowski KP; Ząbczyk M; Butenas S; Undas A
    Eur J Clin Invest; 2023 Sep; 53(9):e14007. PubMed ID: 37042848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased plasma clot permeability and susceptibility to lysis are associated with heavy menstrual bleeding of unknown cause: a case-control study.
    Szczepaniak P; Zabczyk M; Undas A
    PLoS One; 2015; 10(4):e0125069. PubMed ID: 25909989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unfavorably altered fibrin clot properties in patients with active rheumatoid arthritis.
    Kwasny-Krochin B; Gluszko P; Undas A
    Thromb Res; 2010 Jul; 126(1):e11-6. PubMed ID: 20471669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imbalance between Fibrin Clot Formation and Fibrinolysis Predicts Cardiovascular Events in Patients with Stable Coronary Artery Disease.
    Neergaard-Petersen S; Larsen SB; Grove EL; Kristensen SD; Ajjan RA; Hvas AM
    Thromb Haemost; 2020 Jan; 120(1):75-82. PubMed ID: 31733633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.